A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Marc Simon, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Marc Simon, MD
Dr. Simon is director of Pulmonary Vascular Disease and the Pulmonary Hypertension Comprehensive Care Center. He has expertise as a cardiologist specializing in pulmonary hypertension, advanced heart failure, and heart transplantation.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Aerovate Therapeutics
- ID
- NCT05036135
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 462 study participants
- Last Updated